Rhythm Pharmaceuticals Reports Strong Q4 & FY25 Results, Highlights Key Clinical Milestones Including Upcoming PDUFA Date
Summary
Rhythm Pharmaceuticals announced strong Q4 and full year 2025 financial results, featuring significant revenue growth and a reduced net loss, alongside positive clinical updates and a critical PDUFA date for IMCIVREE in acquired hypothalamic obesity.
Key Events
-
Strong Q4 and Full Year 2025 Revenue Growth
Net product revenue from global IMCIVREE sales increased 37% year-over-year to $57.3 million in Q4 2025 and 49.7% to $194.8 million for the full year 2025.
-
Improved Financial Health and Extended Cash Runway
The company significantly reduced its full-year net loss by 23.7% to $201.9 million and increased its cash, cash equivalents, and short-term investments to $388.9 million, providing over 24 months of operational runway.
-
Critical PDUFA Date for IMCIVREE in Acquired Hypothalamic Obesity
A PDUFA goal date of March 20, 2026, is set for the supplemental New Drug Application (sNDA) for setmelanotide in acquired hypothalamic obesity (HO), potentially expanding its market.
-
Positive Clinical Pipeline Updates
Rhythm completed a positive end-of-Phase 2 meeting with the FDA for bivamelagon in acquired HO, showing persistent BMI reductions, and reported positive preliminary Phase 2 results for setmelanotide in Prader-Willi Syndrome (PWS).
Analysis
Rhythm Pharmaceuticals delivered robust financial results for Q4 and full year 2025, marked by significant revenue growth and a reduced net loss, which strengthens its financial position and extends its operational runway. Critically, the company is on the cusp of a major regulatory decision with a PDUFA goal date of March 20, 2026, for IMCIVREE in acquired hypothalamic obesity, which could substantially expand its addressable market. Additionally, positive clinical updates for bivamelagon and setmelanotide, coupled with multiple near-term data readouts, underscore a strong and advancing pipeline, providing multiple potential catalysts for future growth.
At the time of this filing, RYTM was trading at $103.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $45.91 to $122.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.